Pune, India -- (SBWire) -- 04/11/2019 --The latest report on Migraine Drugs Market by Infinium Global Research gives complete coverage of the Migraine Drugs Market by therapeutic class (ergots, triptans), treatment type (abortive, preventive) in terms of key trends, market size, Industry Analysis, Trends, Market Size, Forecasts up to 2024 and CAGR growth over the period of 2018 to 2024. In addition, the study covers deep dive into key product and applications trends in the regional markets of Migraine Drugs such as North America, Europe, Asia-Pacific and Latin America over the short run and long run. The global migraine drugs market is projected to grow at a CAGR of 5.5% over the forecast period of 2018-2024.
For More Details Get FREE Sample Pages of this Premium Global Report@ https://www.infiniumglobalresearch.com/reports/sample-request/1189
Migraine Drugs Market: Industry Insights
Migraine a condition marked by recurring moderate to severe headache with throbbing pain, they can be preceded or accompanied by sensory warning signs and other symptoms. The extreme pain that migraines cause can last for hours or even days. Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels. The global migraine drugs market is exhibiting an 18.0% CAGR during the forecast period.
Migraine Drugs Market: Drivers and Restraints
An increasing number of cases worldwide is driving the global anti-migraine drugs market. Migraine is accounted the third most prevalent and the sixth most disabling illness in the world, affecting more than 37 million in the U.S. and over one billion people worldwide along with it increased number of major pharma investors and government initiatives contributing to the growth of migraine drugs market.
A number of organizations including the American Headache and Migraine Association are taking efforts to spread awareness about migraine and hence coming up with programs and providing support to patients to spread awareness regarding the illness and further disorders related to a headache. On top of it changing lifestyle, increased stress level and rise in prevalence of hormonal imbalance leading to migraine are including high demand for proper medication in the global market, which in turn is driving the global migraine market towards higher verdicts.
However, side effects associated with current migraine drugs like Weakness, Fatigue, Drowsiness, Dizziness, Confusion, Difficulty concentrating, tingling of hands and feet and Loss of appetite along with high drug cost to treat chronic migraine may obstruct the growth of global migraine drugs market during the forecasted years to a certain extent. On the other hand, lack of physical education and training diagnosis rate of migraine is low approximately 50% of episodic migraine and 40% for chronic migraine becoming the major drawback for the migraine drug market.
Request a Discount on Standard Prices of this Premium Report @ https://www.infiniumglobalresearch.com/reports/request-discount/1189
Migraine Drugs Market: Segmentation
The global migraine drugs market is bifurcated on the basis of treatment and therapeutic type, route of administration and others. On the basis of treatment type, the global migraine drugs market is segmented as preventive/prophylactic and abortive/acute. The preventive treatment segment is further sub-segmented as topiramate, botulinum toxin, divalproex sodium, and others. The acute treatment segment is further sub-segmented as ergot, triptans, and others. On the basis of the route of administration, the global market is classified as injectable, oral, subcutaneous, rectal and others. The other segment is further sub-segmented as transdermal patches and nasal sprays.
Migraine Drugs Market: Regional Insight
Migraine is accounted for the most disabling illness in the word. The U.S. dominated the market with the largest share in 2018 and is estimated to maintain the position in the forecast period. Increasing adoption of novel therapeutics, high prevalence and a large target population in the U.S. are some of the factors contributing to the dominance in the market. The Asia Pacific is also projected to maintain a considerable market share, this is due to the increasing number of migraine cases and low production cost of drugs and large underserved patient population.
Browse Complete Global Report and Detailed TOC: https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-migraine-drugs-market
Migraine Drugs Market: Competitive Analysis
Some of the key players in the market are Winston Pharmaceutical, Luitpold Pharmaceutical, GlaxoSmithKline, Eli Lilly, Allergan, Impax Laboratories, Alder Biopharmaceuticals, Pfizer, TG Therapeutics, Aegis Therapeutics, and Johnson & Johnson. Allergan's Botox, a neurotoxin was in a strong competitive position in the preventive migraine market. As the only drug approved for prevention, Botox commanded premium pricing with more than half of the market share in 2017. However, CGRP-based therapies, which target both chronic and episodic migraine proved to be a good competitor to Botox.
Reasons to Buy this Report:
- Comprehensive analysis of global as well as regional markets of the Migraine Drugs.
- Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2024.
- Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
- Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
